Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
Condition: Tick-Borne Encephalitis Interventions: Biological: TBE vaccine 0.5 mL; Biological: TBE vaccine 0.25 mL Sponsor: Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials